| Page 153 | Kisaco Research

Fireside Chat: Innovation and Regulation: Advancing Animal Health Through Constructive Collaboration

Progress in animal health depends on the ability for Innovation and Regulation to work in parallel. This fireside chat explores how regulatory frameworks can enable responsible innovation, support timely market access, and maintain public trust.

The discussion will examine how regulators and industry can engage earlier and more effectively across the innovation lifecycle, from development through commercialisation, to better serve veterinarians, producers, and pet owners. Panellists will share perspectives on current priorities, emerging technologies, and the practical realities of aligning scientific progress with regulatory expectations.

Panellists

Author:

Kristin Peck

Chief Executive Officer

Zoetis

Kristin Peck is Chief Executive Officer and serves on the Board of Zoetis, the world’s leading animal health company and a member of the Fortune 500. With more than 20 years of experience in life sciences and animal health, Ms. Peck is a purpose-driven leader passionate about driving growth through innovation, superior customer experience and colleague empowerment.

Since becoming CEO in 2020, Ms. Peck has guided Zoetis through a volatile macro environment to deliver superior financial growth – with average organic operating topline growth rates that have outpaced both industry growth and historic company performance. Under her leadership, the company’s portfolio has grown to include 18 blockbuster products – and Zoetis has established a robust pipeline with 12 more potential blockbusters (products with expected future potential sales of $100M+) on the horizon – in addition to delivering industry-leading operating margins.

Ms. Peck’s transformative leadership has earned significant distinctions, including being named to the TIME100 Health (2025), CNBC Changemakers (2024), Barron’s Top CEOs (2022) lists and being recognized as a Fortune Businessperson of the Year (2020).

Before joining Zoetis, Ms. Peck served as Executive Vice President, Worldwide Business Development and Innovation, at Pfizer Inc. and as a member of Pfizer's Executive Leadership Team. Earlier in her career, Ms. Peck held roles at Boston Consulting Group, as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan.

Ms. Peck serves on the boards of BlackRock (NYSE: BLK), Mayo Clinic, and Business Roundtable.

She earned a bachelor's degree from Georgetown University and an MBA from Columbia Business School.

Author:

Dr. Timothy Schell

Director for the Center for Veterinary Medicine (CVM)

FDA

Read more about Fireside Chat: Innovation and Regulation: Advancing Animal Health Through Constructive Collaboration

REGISTRATION FOR BRIEFING ATTENDEE ONLY

By registering your interest to these sessions, you are agreeing for your information to be shared with the host.
The host of the workshop reserves the right to refuse entry to any organisation that they feel may be competitive.
You will receive confirmation of workshop registration via email prior to the event.

Read more about REGISTRATION FOR BRIEFING ATTENDEE ONLY

Industry Perspective: Illicit Compounding of Medicines in Europe

An exploration of how illicit compounding intersects with patent protections, market exclusivity, and the proposed EU pharma package revisions shaping the future of pharmaceutical innovation.

Author:

Raquel Frisardi

Associate Corporate Counsel

Novo Nordisk

Read more about Industry Perspective: Illicit Compounding of Medicines in Europe

Interplay Between UPC and National Litigation in the Life Sciences Sector

With the UPC now established, its impact on national litigation in key life sciences jurisdictions is becoming clearer. This session examines how the UPC’s decisions intersect with proceedings in the UK, France, Germany, the Netherlands, and the US. Speakers will explore recent cases, including BSH v. Electrolux and Fujifilm v. Kodak, assessing the reach of the UPC, divergence in substantive law, and the evolving balance between national and supranational enforcement.

Discuss the impact of early UPC rulings on litigation strategies in the UK, France, Germany, and the Netherlands
Analyse the long-arm reach of the UPC and lessons from cases such as BSH v. Electrolux and Fujifilm v. Kodak
Compare how national courts and the UPC apply substantive law in overlapping disputes
Evaluate strategic considerations for coordinating litigation in the UPC versus national and US courts

Author:

Mike Gilbert

Partner

Marks & Clerk

Mike Gilbert is a partner at Marks & Clerk in London. He is an Intellectual Property (IP) lawyer who advises clients in a wide variety of business sectors on issues including litigation and dispute resolution, IP strategy and risk limitation, due diligence projects and commercial and licensing transactions involving IP. His primary focus and expertise, however, lies in life sciences patent litigation where he is considered to be one of the UK’s leading practitioners. He has represented some of the world’s leading biopharmaceutical corporations in complex patent and technical disputes including Genentech, Roche, Chugai, Pfizer, Wyeth, AstraZeneca, MedImmune, Daiichi Sankyo, AbbVie, Amgen and Illumina to name but a few. Mike is well known for his strategic and creative vision and is consistently recommended in various legal directories including the World IP Review, Legal 500, Who's Who Legal and the IAM Patent 1000 guide, which describe him as “always at the top of the pile, especially for pharmaceutical matters”. Mike graduated from Cambridge University in 1989 with a degree in chemical engineering.

Author:

Daniel Hoppe

Partner

Bonabry

Author:

Denis Schertenleib

Partner

Schertenleib Avocats

Author:

Daan De Lange

Partner

Brinkhof

Read more about Interplay Between UPC and National Litigation in the Life Sciences Sector

Decoding G1/23 and Understanding How BOA Decisions Shape Product Launch Strategy

This 20 minute session unpacks the implications of G1/23 and explores how recent Board of Appeal decisions are reshaping product launch strategies in Europe. Gain practical insights into how these rulings affect exclusivity, regulatory interplay, and the timing of market entry.